The Global Cancer Drugs Market Growth Accelerated By Rising Prevalence Of Cancer

 
Cancer Drugs Market

Cancer drugs are pharmaceutical drugs used in chemotherapy for treating various types of cancer. They work by slowing or stopping the growth of cancer cells and reducing the size of tumors. The global Cancer Drugs Market is estimated to be valued at US$ 154.4 billion in 2023 and is expected to exhibit a CAGR of 9.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market key trends: Rising prevalence of cancer across the globe is one of the major factors driving growth of the Cancer Drugs Market. According to the World Health Organization, cancer is a leading cause of death worldwide and accounts for an estimated 9.6 million deaths in 2018. The four most common types of cancer that account for more than half of all new cancer cases are lung, breast, colorectal and prostate cancer. Increasing focus of pharmaceutical companies on development of novel targeted therapeutics as well as growing healthcare expenditure are also contributing to the growth of the market. Advancements in cancer diagnostic techniques have further aided in early detection and treatment of cancer, supporting market growth over the forecast period.
Segment Analysis
The global cancer drugs market is dominated by chemotherapy segment which holds around 35% of the total market share. Chemotherapy is one of the most common treatment options against various cancer types such as breast cancer, lung cancer, blood cancer etc. It works by killing cancer cells or stopping their growth and division. The dominance of chemotherapy is attributed to its broad spectrum anticancer activity against several types of cancer and relatively affordable cost as compared to targeted and biologic therapies.

Key Takeaways
The global Cancer Drugs Market Analysis is expected to witness high. Regional analysis related content comprises the North America region currently dominates the global cancer drugs market with around 45% share. This dominance is attributed to factors such as growing prevalence of cancer, rising healthcare expenditure, availability of advanced treatments and presence of major market players in the region.

Key players operating in the cancer drugs market are Svenska Cellulosa Aktiebolaget SCA, BTG Biomass Technology Group, Eni S.p.A., Fulcrum BioEnergy, SOCOTEC Group, Drax Biomass Inc., Aggregated Micro Power Holdings plc, PVM Environmental Products, VGrid Energy Systems, and Vattenfall AB.

The global cancer drugs market size was valued at US$ 154.4 Bn in 2023 and is projected to reach over US$ 284 Bn by 2030, expanding at a CAGR of around 9.7% during the forecast period. Increasing prevalence of cancer owing to growing geriatric population and changing lifestyle habits are major factors driving the market growth. Additionally, rising adoption of targeted therapies and biologics over conventional chemotherapy drugs will further aid the market expansion over the next few years.

Comments

Post a Comment

Popular posts from this blog

The Global Hydrogen Aircraft Market Is Propel By Hydrogen Fuel Powers Eco-Friendly Aviation

Image
Hydrogen Aircraft Market  Hydrogen fuel cells provide onboard electricity with only water as a byproduct, making them an eco-friendly alternative to conventional jet fuels. Hydrogen fuel cells can power aircraft auxiliary systems and offer a range of over 1,000 nautical miles. The global hydrogen aircraft market is estimated to be valued at  US$ 7.76 Mn in 2023  and is expected to exhibit a  CAGR of 5.0%  over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights. Market key trends: Green Flight Plans Drive Adoption of Hydrogen Technology Major airlines and aircraft manufacturers have announced plans to introduce hydrogen-powered commercial aircraft by 2035 as part of their commitments to achieving net-zero carbon emissions by 2050. The development of hydrogen fuel cell and storage systems suitable for aviation is being pursued through collaborative research programs. Government incentives and potential carbon credit...
Read more

Tissue Paper Market Growth Accelerated By Increasing Demand From Healthcare Facilities

Image
Tissue Paper Market Tissue paper is a lightweight paper which is used for various hygiene and sanitation purposes including toilet paper, facial tissues, paper towels, and napkins. Tissue paper provides softness, strength and absorbency, making it ideal for applications related to healthcare sector such as hospitals, nursing homes, and clinics. The increasing focus on hygiene and sanitation in healthcare facilities is anticipated to propel the demand for tissue paper products over the forecast period. The global Tissue Paper Market is estimated to be valued at   US$ 84.37 Bn   in   2023  and is expected to exhibit a   CAGR of 6.2%   over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: The increasing demand from healthcare sector is one of the major trends boosting the growth of the tissue paper market. With growing healthcare infrastructure and rising spending on healthcare services,...
Read more

Epstein - Barr Virus (EBV) vaccination is fastest growing segment fueling the growth of monovaccine market

Image
Monovaccines  Monovaccines refers to vaccines that provide protection against a single pathogen or disease. EBV monovaccine helps in preventing infectious mononucleosis caused by the Epstein–Barr virus. It offers advantages like conferring lifelong immunity, protection from various cancers associated with EBV infection and reducing disease burden in resource limited countries. The global monovaccine market is estimated to be valued at US$ 10.42 Bn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: One of the major trends in the monovaccine market is rising investment by manufacturers in research and development of EBV vaccines. As per statistics, around 95% of adult population gets infected by EBV at some point in their life making it an attractive target pathogen for vaccination development. Further, increasing awareness about EBV linked cancers lik...
Read more